Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.

Valim V, Martins-Filho OA, Gouvea MDPG, Camacho LAB, Villela DAM, de Lima SMB, Azevedo AS, Neto LFP, Domingues CMAS, de Medeiros Junior NF, Moulaz IR, Dias LH, Miyamoto ST, Teixeira-Carvalho A, Mill JG, Half Dose ChAdOx Study Group

Open source

DOI: 10.3389/fimmu.2022.966416
Published: 2022
Container: Frontiers in immunology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2022.966416,
  title = {Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.},
  author = {Valim V and Martins-Filho OA and Gouvea MDPG and Camacho LAB and Villela DAM and de Lima SMB and Azevedo AS and Neto LFP and Domingues CMAS and de Medeiros Junior NF and Moulaz IR and Dias LH and Miyamoto ST and Teixeira-Carvalho A and Mill JG and Half Dose ChAdOx Study Group},
  year = {2022},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2022.966416},
  url = {https://doi.org/10.3389/fimmu.2022.966416}
}

RIS

TY  - JOUR
TI  - Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
AU  - Valim V
AU  - Martins-Filho OA
AU  - Gouvea MDPG
AU  - Camacho LAB
AU  - Villela DAM
AU  - de Lima SMB
AU  - Azevedo AS
AU  - Neto LFP
AU  - Domingues CMAS
AU  - de Medeiros Junior NF
AU  - Moulaz IR
AU  - Dias LH
AU  - Miyamoto ST
AU  - Teixeira-Carvalho A
AU  - Mill JG
AU  - Half Dose ChAdOx Study Group
PY  - 2022
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2022.966416
UR  - https://doi.org/10.3389/fimmu.2022.966416
ER  -

APA

V, V., OA, M., MDPG, G., LAB, C., DAM, V., SMB, D. L., AS, A., LFP, N., CMAS, D., NF, D. M. J., IR, M., LH, D., ST, M., A, T., JG, M., & Group, H. D. C. S. (2022). Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2022.966416

Source records

pubmed · retrieved 2026-09-27T07:00:47.957Z